nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—Gastrointestinal symptom NOS—Sorafenib—liver cancer	0.0311	0.0312	CcSEcCtD
Brimonidine—Rash papular—Epirubicin—liver cancer	0.0181	0.0182	CcSEcCtD
Brimonidine—Rash papular—Doxorubicin—liver cancer	0.0168	0.0168	CcSEcCtD
Brimonidine—Muscle relaxant therapy—Epirubicin—liver cancer	0.0136	0.0136	CcSEcCtD
Brimonidine—Hypotonia—Epirubicin—liver cancer	0.0128	0.0129	CcSEcCtD
Brimonidine—Muscle relaxant therapy—Doxorubicin—liver cancer	0.0126	0.0126	CcSEcCtD
Brimonidine—Blindness—Epirubicin—liver cancer	0.0122	0.0122	CcSEcCtD
Brimonidine—Dry skin—Sorafenib—liver cancer	0.0122	0.0122	CcSEcCtD
Brimonidine—Body temperature decreased—Epirubicin—liver cancer	0.012	0.0121	CcSEcCtD
Brimonidine—Hypothermia—Epirubicin—liver cancer	0.012	0.0121	CcSEcCtD
Brimonidine—Hypotonia—Doxorubicin—liver cancer	0.0119	0.0119	CcSEcCtD
Brimonidine—Nasopharyngitis—Sorafenib—liver cancer	0.0119	0.0119	CcSEcCtD
Brimonidine—Lacrimation—Epirubicin—liver cancer	0.0115	0.0115	CcSEcCtD
Brimonidine—Blindness—Doxorubicin—liver cancer	0.0113	0.0113	CcSEcCtD
Brimonidine—Hypothermia—Doxorubicin—liver cancer	0.0111	0.0112	CcSEcCtD
Brimonidine—Body temperature decreased—Doxorubicin—liver cancer	0.0111	0.0112	CcSEcCtD
Brimonidine—Lacrimation—Doxorubicin—liver cancer	0.0106	0.0107	CcSEcCtD
Brimonidine—Keratitis—Epirubicin—liver cancer	0.0104	0.0104	CcSEcCtD
Brimonidine—Burning sensation—Epirubicin—liver cancer	0.00972	0.00975	CcSEcCtD
Brimonidine—Keratitis—Doxorubicin—liver cancer	0.00963	0.00967	CcSEcCtD
Brimonidine—Burning sensation—Doxorubicin—liver cancer	0.00899	0.00903	CcSEcCtD
Brimonidine—Scotoma—Epirubicin—liver cancer	0.00889	0.00892	CcSEcCtD
Brimonidine—Feeling hot—Epirubicin—liver cancer	0.0086	0.00863	CcSEcCtD
Brimonidine—Flushing—Sorafenib—liver cancer	0.00852	0.00855	CcSEcCtD
Brimonidine—Cardiac disorder—Sorafenib—liver cancer	0.00852	0.00855	CcSEcCtD
Brimonidine—Stinging—Epirubicin—liver cancer	0.00833	0.00836	CcSEcCtD
Brimonidine—Angiopathy—Sorafenib—liver cancer	0.00832	0.00835	CcSEcCtD
Brimonidine—Immune system disorder—Sorafenib—liver cancer	0.00829	0.00832	CcSEcCtD
Brimonidine—Mediastinal disorder—Sorafenib—liver cancer	0.00827	0.0083	CcSEcCtD
Brimonidine—Scotoma—Doxorubicin—liver cancer	0.00823	0.00826	CcSEcCtD
Brimonidine—Arrhythmia—Sorafenib—liver cancer	0.0082	0.00823	CcSEcCtD
Brimonidine—Mental disorder—Sorafenib—liver cancer	0.00804	0.00807	CcSEcCtD
Brimonidine—Erythema—Sorafenib—liver cancer	0.00799	0.00802	CcSEcCtD
Brimonidine—Feeling hot—Doxorubicin—liver cancer	0.00796	0.00799	CcSEcCtD
Brimonidine—Dysgeusia—Sorafenib—liver cancer	0.00782	0.00785	CcSEcCtD
Brimonidine—Stinging—Doxorubicin—liver cancer	0.00771	0.00774	CcSEcCtD
Brimonidine—Vasodilation—Epirubicin—liver cancer	0.00769	0.00771	CcSEcCtD
Brimonidine—Vasodilation procedure—Epirubicin—liver cancer	0.00769	0.00771	CcSEcCtD
Brimonidine—Arthropathy—Epirubicin—liver cancer	0.00743	0.00745	CcSEcCtD
Brimonidine—Lacrimation increased—Epirubicin—liver cancer	0.00733	0.00735	CcSEcCtD
Brimonidine—Syncope—Sorafenib—liver cancer	0.00716	0.00719	CcSEcCtD
Brimonidine—Vasodilation—Doxorubicin—liver cancer	0.00711	0.00714	CcSEcCtD
Brimonidine—Vasodilation procedure—Doxorubicin—liver cancer	0.00711	0.00714	CcSEcCtD
Brimonidine—Loss of consciousness—Sorafenib—liver cancer	0.00702	0.00705	CcSEcCtD
Brimonidine—Cough—Sorafenib—liver cancer	0.00697	0.00699	CcSEcCtD
Brimonidine—Hypertension—Sorafenib—liver cancer	0.0069	0.00692	CcSEcCtD
Brimonidine—Arthropathy—Doxorubicin—liver cancer	0.00687	0.0069	CcSEcCtD
Brimonidine—Myalgia—Sorafenib—liver cancer	0.0068	0.00682	CcSEcCtD
Brimonidine—Arthralgia—Sorafenib—liver cancer	0.0068	0.00682	CcSEcCtD
Brimonidine—Lacrimation increased—Doxorubicin—liver cancer	0.00678	0.0068	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00675	0.00678	CcSEcCtD
Brimonidine—Dermatitis contact—Epirubicin—liver cancer	0.00667	0.0067	CcSEcCtD
Brimonidine—Dry mouth—Sorafenib—liver cancer	0.00665	0.00667	CcSEcCtD
Brimonidine—Infection—Sorafenib—liver cancer	0.00648	0.0065	CcSEcCtD
Brimonidine—Shock—Sorafenib—liver cancer	0.00641	0.00644	CcSEcCtD
Brimonidine—Nervous system disorder—Sorafenib—liver cancer	0.00639	0.00642	CcSEcCtD
Brimonidine—Skin disorder—Sorafenib—liver cancer	0.00633	0.00635	CcSEcCtD
Brimonidine—Dry eye—Epirubicin—liver cancer	0.00624	0.00626	CcSEcCtD
Brimonidine—Dermatitis contact—Doxorubicin—liver cancer	0.00617	0.0062	CcSEcCtD
Brimonidine—Coma—Epirubicin—liver cancer	0.00617	0.00619	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00594	0.00596	CcSEcCtD
Brimonidine—Abnormal vision—Epirubicin—liver cancer	0.00589	0.00591	CcSEcCtD
Brimonidine—Dyspnoea—Sorafenib—liver cancer	0.00581	0.00583	CcSEcCtD
Brimonidine—Dry eye—Doxorubicin—liver cancer	0.00577	0.00579	CcSEcCtD
Brimonidine—Dyspepsia—Sorafenib—liver cancer	0.00574	0.00576	CcSEcCtD
Brimonidine—Coma—Doxorubicin—liver cancer	0.00571	0.00573	CcSEcCtD
Brimonidine—Diabetes mellitus—Epirubicin—liver cancer	0.00564	0.00566	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Sorafenib—liver cancer	0.00563	0.00565	CcSEcCtD
Brimonidine—Fatigue—Sorafenib—liver cancer	0.00562	0.00564	CcSEcCtD
Brimonidine—Pain—Sorafenib—liver cancer	0.00557	0.00559	CcSEcCtD
Brimonidine—Abnormal vision—Doxorubicin—liver cancer	0.00545	0.00547	CcSEcCtD
Brimonidine—Eye pain—Epirubicin—liver cancer	0.00543	0.00545	CcSEcCtD
Brimonidine—Diabetes mellitus—Doxorubicin—liver cancer	0.00521	0.00523	CcSEcCtD
Brimonidine—Eye pain—Doxorubicin—liver cancer	0.00502	0.00504	CcSEcCtD
Brimonidine—Lethargy—Epirubicin—liver cancer	0.005	0.00502	CcSEcCtD
Brimonidine—Osteoarthritis—Epirubicin—liver cancer	0.0049	0.00492	CcSEcCtD
Brimonidine—Hypersensitivity—Sorafenib—liver cancer	0.0048	0.00482	CcSEcCtD
Brimonidine—Face oedema—Epirubicin—liver cancer	0.00473	0.00475	CcSEcCtD
Brimonidine—Asthenia—Sorafenib—liver cancer	0.00468	0.00469	CcSEcCtD
Brimonidine—Lethargy—Doxorubicin—liver cancer	0.00463	0.00464	CcSEcCtD
Brimonidine—Pruritus—Sorafenib—liver cancer	0.00461	0.00463	CcSEcCtD
Brimonidine—Osteoarthritis—Doxorubicin—liver cancer	0.00454	0.00455	CcSEcCtD
Brimonidine—Dry skin—Epirubicin—liver cancer	0.00449	0.00451	CcSEcCtD
Brimonidine—Nasopharyngitis—Epirubicin—liver cancer	0.00438	0.0044	CcSEcCtD
Brimonidine—Face oedema—Doxorubicin—liver cancer	0.00438	0.00439	CcSEcCtD
Brimonidine—Dizziness—Sorafenib—liver cancer	0.00431	0.00433	CcSEcCtD
Brimonidine—Influenza—Epirubicin—liver cancer	0.00424	0.00425	CcSEcCtD
Brimonidine—Dry skin—Doxorubicin—liver cancer	0.00416	0.00417	CcSEcCtD
Brimonidine—Rash—Sorafenib—liver cancer	0.00411	0.00412	CcSEcCtD
Brimonidine—Dermatitis—Sorafenib—liver cancer	0.00411	0.00412	CcSEcCtD
Brimonidine—Headache—Sorafenib—liver cancer	0.00408	0.0041	CcSEcCtD
Brimonidine—Bronchitis—Epirubicin—liver cancer	0.00407	0.00409	CcSEcCtD
Brimonidine—Nasopharyngitis—Doxorubicin—liver cancer	0.00406	0.00407	CcSEcCtD
Brimonidine—Influenza—Doxorubicin—liver cancer	0.00392	0.00393	CcSEcCtD
Brimonidine—Nausea—Sorafenib—liver cancer	0.00387	0.00389	CcSEcCtD
Brimonidine—Drowsiness—Epirubicin—liver cancer	0.00378	0.00379	CcSEcCtD
Brimonidine—Bronchitis—Doxorubicin—liver cancer	0.00377	0.00378	CcSEcCtD
Brimonidine—Conjunctivitis—Epirubicin—liver cancer	0.00367	0.00368	CcSEcCtD
Brimonidine—Clonidine—CYP1A1—liver cancer	0.00355	1	CrCbGaD
Brimonidine—Sinusitis—Epirubicin—liver cancer	0.00354	0.00356	CcSEcCtD
Brimonidine—Drowsiness—Doxorubicin—liver cancer	0.0035	0.00351	CcSEcCtD
Brimonidine—Bradycardia—Epirubicin—liver cancer	0.00345	0.00346	CcSEcCtD
Brimonidine—Rhinitis—Epirubicin—liver cancer	0.0034	0.00341	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—liver cancer	0.0034	0.00341	CcSEcCtD
Brimonidine—Pharyngitis—Epirubicin—liver cancer	0.00337	0.00338	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—liver cancer	0.00328	0.00329	CcSEcCtD
Brimonidine—Visual impairment—Epirubicin—liver cancer	0.00327	0.00328	CcSEcCtD
Brimonidine—Bradycardia—Doxorubicin—liver cancer	0.00319	0.00321	CcSEcCtD
Brimonidine—Eye disorder—Epirubicin—liver cancer	0.00317	0.00318	CcSEcCtD
Brimonidine—Flushing—Epirubicin—liver cancer	0.00315	0.00316	CcSEcCtD
Brimonidine—Cardiac disorder—Epirubicin—liver cancer	0.00315	0.00316	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—liver cancer	0.00315	0.00316	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—liver cancer	0.00311	0.00313	CcSEcCtD
Brimonidine—Angiopathy—Epirubicin—liver cancer	0.00308	0.00309	CcSEcCtD
Brimonidine—Immune system disorder—Epirubicin—liver cancer	0.00306	0.00307	CcSEcCtD
Brimonidine—Mediastinal disorder—Epirubicin—liver cancer	0.00306	0.00307	CcSEcCtD
Brimonidine—Arrhythmia—Epirubicin—liver cancer	0.00303	0.00304	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—liver cancer	0.00302	0.00303	CcSEcCtD
Brimonidine—Mental disorder—Epirubicin—liver cancer	0.00297	0.00298	CcSEcCtD
Brimonidine—Erythema—Epirubicin—liver cancer	0.00295	0.00296	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—liver cancer	0.00293	0.00294	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—liver cancer	0.00291	0.00292	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—liver cancer	0.00291	0.00292	CcSEcCtD
Brimonidine—Dysgeusia—Epirubicin—liver cancer	0.00289	0.0029	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—liver cancer	0.00285	0.00286	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—liver cancer	0.00283	0.00284	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—liver cancer	0.00283	0.00284	CcSEcCtD
Brimonidine—Arrhythmia—Doxorubicin—liver cancer	0.0028	0.00281	CcSEcCtD
Brimonidine—Vision blurred—Epirubicin—liver cancer	0.00278	0.00279	CcSEcCtD
Brimonidine—Mental disorder—Doxorubicin—liver cancer	0.00275	0.00276	CcSEcCtD
Brimonidine—Erythema—Doxorubicin—liver cancer	0.00273	0.00274	CcSEcCtD
Brimonidine—Dysgeusia—Doxorubicin—liver cancer	0.00267	0.00268	CcSEcCtD
Brimonidine—Syncope—Epirubicin—liver cancer	0.00265	0.00266	CcSEcCtD
Brimonidine—Palpitations—Epirubicin—liver cancer	0.00261	0.00262	CcSEcCtD
Brimonidine—Loss of consciousness—Epirubicin—liver cancer	0.00259	0.0026	CcSEcCtD
Brimonidine—Cough—Epirubicin—liver cancer	0.00258	0.00259	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—liver cancer	0.00257	0.00258	CcSEcCtD
Brimonidine—Hypertension—Epirubicin—liver cancer	0.00255	0.00256	CcSEcCtD
Brimonidine—Arthralgia—Epirubicin—liver cancer	0.00251	0.00252	CcSEcCtD
Brimonidine—Myalgia—Epirubicin—liver cancer	0.00251	0.00252	CcSEcCtD
Brimonidine—Chest pain—Epirubicin—liver cancer	0.00251	0.00252	CcSEcCtD
Brimonidine—Anxiety—Epirubicin—liver cancer	0.0025	0.00251	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.0025	0.0025	CcSEcCtD
Brimonidine—Discomfort—Epirubicin—liver cancer	0.00248	0.00249	CcSEcCtD
Brimonidine—Dry mouth—Epirubicin—liver cancer	0.00246	0.00247	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—liver cancer	0.00245	0.00246	CcSEcCtD
Brimonidine—Palpitations—Doxorubicin—liver cancer	0.00241	0.00242	CcSEcCtD
Brimonidine—Oedema—Epirubicin—liver cancer	0.00241	0.00242	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—liver cancer	0.0024	0.00241	CcSEcCtD
Brimonidine—Infection—Epirubicin—liver cancer	0.00239	0.0024	CcSEcCtD
Brimonidine—Cough—Doxorubicin—liver cancer	0.00238	0.00239	CcSEcCtD
Brimonidine—Shock—Epirubicin—liver cancer	0.00237	0.00238	CcSEcCtD
Brimonidine—Nervous system disorder—Epirubicin—liver cancer	0.00236	0.00237	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—liver cancer	0.00236	0.00237	CcSEcCtD
Brimonidine—Tachycardia—Epirubicin—liver cancer	0.00235	0.00236	CcSEcCtD
Brimonidine—Skin disorder—Epirubicin—liver cancer	0.00234	0.00235	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—liver cancer	0.00233	0.00233	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—liver cancer	0.00233	0.00233	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—liver cancer	0.00233	0.00233	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—liver cancer	0.00232	0.00233	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00231	0.00232	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—liver cancer	0.0023	0.00231	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—liver cancer	0.00227	0.00228	CcSEcCtD
Brimonidine—Hypotension—Epirubicin—liver cancer	0.00225	0.00226	CcSEcCtD
Brimonidine—Oedema—Doxorubicin—liver cancer	0.00223	0.00224	CcSEcCtD
Brimonidine—Infection—Doxorubicin—liver cancer	0.00221	0.00222	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00219	0.0022	CcSEcCtD
Brimonidine—Shock—Doxorubicin—liver cancer	0.00219	0.0022	CcSEcCtD
Brimonidine—Nervous system disorder—Doxorubicin—liver cancer	0.00219	0.00219	CcSEcCtD
Brimonidine—Insomnia—Epirubicin—liver cancer	0.00218	0.00219	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—liver cancer	0.00218	0.00218	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—liver cancer	0.00217	0.00217	CcSEcCtD
Brimonidine—Paraesthesia—Epirubicin—liver cancer	0.00216	0.00217	CcSEcCtD
Brimonidine—Dyspnoea—Epirubicin—liver cancer	0.00215	0.00216	CcSEcCtD
Brimonidine—Somnolence—Epirubicin—liver cancer	0.00214	0.00215	CcSEcCtD
Brimonidine—Dyspepsia—Epirubicin—liver cancer	0.00212	0.00213	CcSEcCtD
Brimonidine—Hypotension—Doxorubicin—liver cancer	0.00208	0.00209	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Epirubicin—liver cancer	0.00208	0.00209	CcSEcCtD
Brimonidine—Fatigue—Epirubicin—liver cancer	0.00208	0.00208	CcSEcCtD
Brimonidine—Pain—Epirubicin—liver cancer	0.00206	0.00207	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00203	0.00204	CcSEcCtD
Brimonidine—Insomnia—Doxorubicin—liver cancer	0.00202	0.00202	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—liver cancer	0.002	0.00201	CcSEcCtD
Brimonidine—Dyspnoea—Doxorubicin—liver cancer	0.00199	0.00199	CcSEcCtD
Brimonidine—Somnolence—Doxorubicin—liver cancer	0.00198	0.00199	CcSEcCtD
Brimonidine—Dyspepsia—Doxorubicin—liver cancer	0.00196	0.00197	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00192	0.00193	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—liver cancer	0.00192	0.00193	CcSEcCtD
Brimonidine—Pain—Doxorubicin—liver cancer	0.00191	0.00191	CcSEcCtD
Brimonidine—Hypersensitivity—Epirubicin—liver cancer	0.00177	0.00178	CcSEcCtD
Brimonidine—Asthenia—Epirubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Brimonidine—Pruritus—Epirubicin—liver cancer	0.0017	0.00171	CcSEcCtD
Brimonidine—Hypersensitivity—Doxorubicin—liver cancer	0.00164	0.00165	CcSEcCtD
Brimonidine—Asthenia—Doxorubicin—liver cancer	0.0016	0.00161	CcSEcCtD
Brimonidine—Dizziness—Epirubicin—liver cancer	0.00159	0.0016	CcSEcCtD
Brimonidine—Pruritus—Doxorubicin—liver cancer	0.00158	0.00158	CcSEcCtD
Brimonidine—Rash—Epirubicin—liver cancer	0.00152	0.00152	CcSEcCtD
Brimonidine—Dermatitis—Epirubicin—liver cancer	0.00152	0.00152	CcSEcCtD
Brimonidine—Headache—Epirubicin—liver cancer	0.00151	0.00151	CcSEcCtD
Brimonidine—Dizziness—Doxorubicin—liver cancer	0.00147	0.00148	CcSEcCtD
Brimonidine—Nausea—Epirubicin—liver cancer	0.00143	0.00144	CcSEcCtD
Brimonidine—Rash—Doxorubicin—liver cancer	0.00141	0.00141	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—liver cancer	0.0014	0.00141	CcSEcCtD
Brimonidine—Headache—Doxorubicin—liver cancer	0.0014	0.0014	CcSEcCtD
Brimonidine—Nausea—Doxorubicin—liver cancer	0.00132	0.00133	CcSEcCtD
